Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial (Q38160956)

30 August 2017

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial (English)

1 reference

30 August 2017

phase III clinical trial

0 references

author

Viktor Stus

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Thomas E Hutson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Vladimir Lesovoy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Salman Al-Shukri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Oleg N Lipatov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Angel H Bair

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Brad Rosbrook

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Connie Chen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sinil Kim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Nicholas J Vogelzang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

25 October 2013

1 reference

Lancet Oncology Commission

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

1287-1294

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Development and validation of a scale to measure disease-related symptoms of kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970465-0

7 January 2021

10.1016/S1470-2045(13)70465-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24206640%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference